Across 56 Form 4 filings spanning three companies, Hunt Anthony has executed a one-sided pattern of open-market sales with no corresponding purchases. The CEO’s total sell value reached $17.9 million, while buy and acquisition values sat at zero. The most concentrated activity occurred in Repligen (RGEN), where a cluster of 17 sales between September 2025 and November 2025 generated roughly $10.6 million. Notable single-day dispositions on November 12 and November 13, 2025, included multiple tranches ranging from $73,548 to $1.75 million, often paired with option exercises (code M) that added shares before immediate sale.
The remaining sell volume came from a September 10, 2025, batch of five RGEN trades totaling $3.5 million, with individual values from $131,098 to $1.79 million. Outside RGEN, activity was limited to non-sale events: equity awards (code A) in 2026 for 908 Devices (MASS) and BioLife Solutions (BLFS), a tax-withholding disposition (code F) in RGEN worth $1.24 million in March 2026, and a derivative conversion (code J) with no cash value. No open-market buys (code P) appear in the record, and the recent 17 trades are all sales or compensation-linked events.
The trajectory is unambiguous: Anthony has been a consistent net seller of RGEN shares over the past year, with the largest dollar amounts concentrated in November 2025. The absence of any purchase activity, even at lower price points, reinforces a sustained distribution posture. While the MASS and BLFS grants add share count without cash outlay, they do not offset the substantial realized proceeds from RGEN sales. The data shows a CEO monetizing equity positions across a narrow window, with no counterbalancing accumulation in any of the three holdings.
AI-assisted summary